A study performed at the University of São Paulo’s Biomedical Science Institute (ICB-USP) in Brazil shows that sofosbuvir, a drug used to treat chronic hepatitis C, is capable of eliminating chikungunya virus and yellow fever virus.
“Human cells infected by chikungunya virus were treated with sofosbuvir, and the drug eliminated the virus without damaging any cells. The drug proved to be 11 times more effective against the virus than against cells,” said Rafaela Milan Bonotto, a coauthor of the study.
An article on the study, signed by Bonotto, Freitas-Junior and collaborators, can be found on the open platform F1000Research. An article on the group’s research relating to yellow fever will be published shortly.
The discovery is highly significant for public health, as a chikungunya epidemic has been forecast for the coming two years in Brazil.
“Drug development is extremely costly and time-consuming. The process takes 12 years on average between the start of research and bringing the drug to market. The cost is on the order of US$1.5 billion or more,” Freitas-Junior said. “Sofosbuvir has been fully approved for human use. This means it can be readied for use against chikungunya in one to three years, for a much lower cost, estimated at approximately US$500,000.”
He noted that chikungunya is a severe disease not only owing to the acute episode itself – causing symptoms similar to those of dengue – but because it can cause complications that include highly debilitating joint pain lasting months or years. The patient may become incapacitated, unable to work and even bedridden.
“So far we have no vaccine, and our diagnostic tools need to be optimized,” he continued. “Sofosbuvir is something concrete that could become a powerful weapon against this virus. The results of our research could enable any interested institutions to begin clinical trials.”
Bonotto said, “We don’t yet know exactly how the drug works in molecular terms. What we discovered was the macroscopic result: elimination of the virus and preservation of cells. The drug has proven effective in treating hepatitis C because it inhibits the protein that synthesizes the viral genome. The same may happen in the case of chikungunya, but the action mechanism must be elucidated.”
The Latest on: Sofosbuvir
via Google News
The Latest on: Sofosbuvir
- Sofosbuvir Market Overview, Industry Top Manufactures, Size, Growth rate 2020-2026on January 14, 2020 at 3:35 am
Market Study Report, LLC, has added the latest research on Sofosbuvir Market which offers a concise outline of the market valuation, industry size, SWOT analysis, revenue approximation, and the ...
- Global & China Sofosbuvir Market Insights Analysis and Forecast 2019-2024 - ResearchAndMarkets.comon December 30, 2019 at 3:44 am
The "Sofosbuvir Market Insights 2019, Analysis and Forecast Global and Chinese Market to 2024, by Manufacturers, Product Type, Application, Regions and Technology" report has been added to ...
- Global & China Sofosbuvir Market Insights Analysis and Forecast 2019-2024 - ResearchAndMarkets.comon December 30, 2019 at 3:40 am
DUBLIN--(BUSINESS WIRE)--The "Sofosbuvir Market Insights 2019, Analysis and Forecast Global and Chinese Market to 2024, by Manufacturers, Product Type, Application, Regions and Technology" report ...
- Taiwan National Health Insurance Adminstration of the Ministry of Health and Welfare Approves Epclusa(R) (sofosbuvir/velpatasvir) for Reimbursementon May 29, 2019 at 11:22 pm
TAIPEI, Taiwan, May 30, 2019 /PRNewswire/ -- Gilead Sciences, Inc. today announced that Epclusa (sofosbuvir 400mg/velpatasvir 100mg), a once daily pan-genotypic, pan-fibrotic and interferon-free ...
- Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infectionon February 15, 2019 at 4:00 pm
Objectives: Chronic hepatitis C-infected patients who do not respond to nonstructural 5A inhibitor-containing regimens have few treatment options. It is unclear if ...
- Sofosbuvir rids organism of chikungunya and yellow fever viruseson December 19, 2018 at 4:53 am
A study performed at the University of São Paulo's Biomedical Science Institute (ICB-USP) in Brazil shows that sofosbuvir, a drug used to treat chronic hepatitis C, is capable of eliminating ...
- Sofosbuvir - Indications, Dosage, Side Effects and Precautionson October 31, 2018 at 4:34 am
Latest prescription information about Sofosbuvir. Learn how to pronounce the drug's name, its indications, dosage, how to take, when to take, when not to take, side effects, special precautions ...
- Sofosbuvir-based DAAs effective for most genotypes in Chinese patientson March 27, 2018 at 1:28 pm
Sofosbuvir plus ribavirin with or without pegylated interferon was safe and effective in Chinese patients with hepatitis C genotypes 1, 2, 3 and 6, regardless of treatment experience, according to ...
via Bing News